

SINGAPORE MEDICAL GROUP LIMITED

(Incorporated in the Republic of Singapore)

(UEN/Company Registration No. 200503187W)

ANNOUNCEMENT

SETTLEMENT OF THE INVITATION TO NOTEHOLDERS TO OFFER TO SELL FOR CASH S\$90,000,000 3.54 PER CENT. NOTES DUE 2029 (ISIN: SGXF13889278) GUARANTEED BY CREDIT GUARANTEE AND INVESTMENT FACILITY, A TRUST FUND OF THE ASIAN DEVELOPMENT BANK

The Singapore Exchange Securities Trading Limited (the "SGX-ST") takes no responsibility for the contents of this announcement, makes no representation as to its accuracy or completeness and expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities or an invitation to enter into an agreement to do any such things, nor is it calculated to invite any offer to acquire, purchase or subscribe for any securities.

1. INTRODUCTION

Singapore Medical Group Limited (the "**Issuer**") refers to:

- (a) its announcement dated 13 August 2026 (the "**Invitation Announcement**") in relation to the invitation (the "**Invitation**") to holders (the "**Noteholders**") of its outstanding S\$90,000,000 3.54 per cent. Notes due 2029 (ISIN: SGXF13889278) (the "**Notes**") guaranteed by Credit Guarantee and Investment Facility, a trust fund of the Asian Development Bank (the "**Guarantor**"), to offer to sell for cash to the Issuer up to S\$31,500,000 in aggregate principal amount of the outstanding Notes held by Noteholders, subject to the terms and conditions set out in the invitation memorandum dated 13 August 2026 (the "**Invitation Memorandum**");
- (b) its announcement dated 21 August 2026 in relation to the extension of the Expiration Deadline to 5:30 p.m. (Singapore time) on 26 August 2026 and the Settlement Date to 31 August 2026; and
- (c) its announcement dated 28 August 2026 in relation to the results of the Invitation (the "**Results Announcement**"), pursuant to which the Issuer announced that it would accept for purchase S\$31,500,000 in aggregate principal amount of the Notes (the "**Final Accepted Notes**").

Capitalised terms used but not defined herein shall have the meanings given to them in the Invitation Memorandum.

2. SETTLEMENT OF THE INVITATION

The Issuer hereby announces that settlement of the Invitation was completed on 31 August 2026.

Pursuant to the Invitation, the Issuer has purchased S\$31,500,000 in aggregate principal amount of the Final Accepted Notes. Noteholders whose Notes were accepted for purchase have received:

- (a) the Purchase Price of 104.850 per cent. of the principal amount of the Final Accepted Notes, being S\$262,125 for each S\$250,000 in principal amount of Notes; and
- (b) the Accrued Interest on the Final Accepted Notes from (and including) 20 May 2026 up to (but excluding) 31 August 2026.

The Final Accepted Notes purchased by the Issuer pursuant to the Invitation will be cancelled in accordance with the terms of the Invitation Memorandum.

3. NOTES REMAINING OUTSTANDING

Following settlement of the Invitation and cancellation of the Final Accepted Notes, S\$58,500,000 in aggregate principal amount of the Notes remains outstanding.

4. DEALER MANAGERS AND TENDER AGENT

Questions or requests for information in relation to the Invitation should be directed to:

Dealer Managers

DBS Bank Ltd.

12 Marina Boulevard
Level 42, Marina Bay Financial Centre Tower 3
Singapore 018982
Telephone: +65 6222 4261
Facsimile: +65 6225 7464
Email: liabilitymanagement@dbs.com

Oversea-Chinese Banking Corporation Limited

63 Chulia Street
#03-01 OCBC Centre East
Singapore 049514
Email: liabilitymanagement@ocbc.com

Questions or requests for information in relation to the Invitation and the submission of Tender Application Forms should be directed to:

Tender Agent

Tricor Barbinder Share Registration Services

(a division of Tricor Singapore Pte. Ltd.)
9 Raffles Place
#26-01 Republic Plaza
Singapore 048619
Telephone: +65 6236 3555
Email: is.corporateactions@vistra.com

5. IMPORTANT NOTICE

None of the Issuer, the Guarantor, the Dealer Managers, the Trustee or the Tender Agent makes any representation or recommendation as to the merits of the Invitation.

By Order of the Board

SINGAPORE MEDICAL GROUP LIMITED

Dr Beng Teck Liang
Executive Director and Chief Executive Officer

31 August 2026